RenovoRx, Inc. (NASDAQ:RNXT - Get Free Report) insider Ramtin Agah acquired 20,000 shares of the business's stock in a transaction dated Friday, April 11th. The shares were bought at an average price of $0.80 per share, with a total value of $16,000.00. Following the transaction, the insider now directly owns 1,098,460 shares in the company, valued at approximately $878,768. The trade was a 1.85 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Ramtin Agah also recently made the following trade(s):
- On Tuesday, April 8th, Ramtin Agah bought 26,000 shares of RenovoRx stock. The shares were bought at an average cost of $0.84 per share, for a total transaction of $21,840.00.
RenovoRx Stock Performance
Shares of NASDAQ:RNXT opened at $0.84 on Tuesday. RenovoRx, Inc. has a 52 week low of $0.75 and a 52 week high of $1.69. The company has a market cap of $20.28 million, a PE ratio of -1.48 and a beta of 1.12. The firm has a 50 day simple moving average of $0.98 and a 200 day simple moving average of $1.13.
RenovoRx (NASDAQ:RNXT - Get Free Report) last issued its earnings results on Monday, March 31st. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.17 million. On average, equities analysts predict that RenovoRx, Inc. will post -0.4 earnings per share for the current year.
Analyst Ratings Changes
Separately, HC Wainwright restated a "buy" rating and set a $3.00 price objective on shares of RenovoRx in a report on Friday, April 4th.
View Our Latest Stock Analysis on RNXT
Institutional Investors Weigh In On RenovoRx
Institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new stake in shares of RenovoRx in the fourth quarter worth approximately $49,000. Renaissance Technologies LLC acquired a new position in RenovoRx in the 4th quarter valued at approximately $84,000. Finally, Geode Capital Management LLC lifted its position in RenovoRx by 61.9% in the 3rd quarter. Geode Capital Management LLC now owns 232,937 shares of the company's stock worth $247,000 after buying an additional 89,018 shares in the last quarter. 3.10% of the stock is currently owned by institutional investors and hedge funds.
About RenovoRx
(
Get Free Report)
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
